Received Mar 20, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 2 | Unknown | PO / MO |
The patient took first two doses of Vivotif, two days in row; Case reference number US-BN-2024-001982 is a spontaneous case initially received from pharmacist via Communications (reference number: USBAV23-1231) on 03-Jun-2024 and concerns female patient of unspecified age. The patient's relevant medical history and concomitant medication details were not provided. On unspecified days, as reported two days in a row, the patient took the first and the second dose of Vivotif (batch number: unknown), at unknown dose, orally, for typhoid immunization (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif. Additional information received from Communications on 03-Jun-2024 included Vivotif indication and new reference number (USBAV23-1227). Non-significant follow up was downloaded from VAERS on 09-May-2025 included new reference number Administrative update performed within the case: Worldwide Unique Case Identification Number (WWID) updated from US-20240603-fa050a to US-BAVARIAN NORDIC A/S-US-BN-2024-001982, in accordance with ICH guidance on WWID formatting.; Reporter's Comments: A female patient of unspecified age took the first and the second dose of Vivotif, two days in a row, at unknown dose, orally, for typhoid immunization which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to Vivotif. The patient's relevant medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A female patient of unspecified age took the first and the second dose of Vivotif, two days in a row, at unknown dose, orally, for typhoid immunization which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to Vivotif. The patient's relevant medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.
Comments: None.